Published in Cell on February 21, 1992
Kinetic proofreading in T-cell receptor signal transduction. Proc Natl Acad Sci U S A (1995) 5.01
Kinetics of T-cell receptor binding to peptide/I-Ek complexes: correlation of the dissociation rate with T-cell responsiveness. Proc Natl Acad Sci U S A (1994) 3.07
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol (2011) 2.55
Kinetic discrimination in T-cell activation. Proc Natl Acad Sci U S A (1996) 2.17
Structure of a covalently stabilized complex of a human alphabeta T-cell receptor, influenza HA peptide and MHC class II molecule, HLA-DR1. EMBO J (2000) 2.00
Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells. J Exp Med (1999) 1.70
Comparison of peptides bound to spleen and thymus class II. J Exp Med (1993) 1.59
Selective expansion of cross-reactive CD8(+) memory T cells by viral variants. J Exp Med (1999) 1.58
Immunobiology of cytotoxic T-cell escape mutants of lymphocytic choriomeningitis virus. J Virol (1995) 1.56
Kinetics and extent of T cell activation as measured with the calcium signal. J Exp Med (1997) 1.51
Mature T cell reactivity altered by peptide agonist that induces positive selection. J Exp Med (1996) 1.50
Costimulation of T cell activation by integrin-associated protein (CD47) is an adhesion-dependent, CD28-independent signaling pathway. J Exp Med (1997) 1.49
Structural basis for T cell recognition of altered peptide ligands: a single T cell receptor can productively recognize a large continuum of related ligands. J Exp Med (1996) 1.48
Antigens varying in affinity for the B cell receptor induce differential B lymphocyte responses. J Exp Med (1998) 1.47
Partial signaling by CD8+ T cells in response to antagonist ligands. J Exp Med (1996) 1.41
HIV-1 variation diminishes CD4 T lymphocyte recognition. J Exp Med (1998) 1.36
A kinetic threshold between negative and positive selection based on the longevity of the T cell receptor-ligand complex. J Exp Med (1999) 1.36
A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens. Proc Natl Acad Sci U S A (1997) 1.33
The efficiency of CD4 recruitment to ligand-engaged TCR controls the agonist/partial agonist properties of peptide-MHC molecule ligands. J Exp Med (1997) 1.33
A polyalanine peptide with only five native myelin basic protein residues induces autoimmune encephalomyelitis. J Exp Med (1992) 1.31
T cell receptor interaction with peptide/major histocompatibility complex (MHC) and superantigen/MHC ligands is dominated by antigen. J Exp Med (1993) 1.31
Differential functional avidity of dengue virus-specific T-cell clones for variant peptides representing heterologous and previously encountered serotypes. J Virol (2007) 1.24
Effect of T-cell receptor antagonism on interaction between T cells and antigen-presenting cells and on T-cell signaling events. Proc Natl Acad Sci U S A (1993) 1.21
Antagonism of superantigen-stimulated helper T-cell clones and hybridomas by altered peptide ligand. Proc Natl Acad Sci U S A (1994) 1.20
Amino acid residues that flank core peptide epitopes and the extracellular domains of CD4 modulate differential signaling through the T cell receptor. J Exp Med (1994) 1.19
Altered ligands reveal limited plasticity in the T cell response to a pathogenic epitope. J Exp Med (1999) 1.17
Partially phosphorylated T cell receptor zeta molecules can inhibit T cell activation. J Exp Med (1999) 1.16
Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc Natl Acad Sci U S A (1999) 1.16
Negative selection of CD4+ CD8+ thymocytes by T-cell receptor peptide antagonists. Proc Natl Acad Sci U S A (1994) 1.15
T cell receptor (TCR) antagonism without a negative signal: evidence from T cell hybridomas expressing two independent TCRs. J Exp Med (1999) 1.15
Disease inhibition by major histocompatibility complex binding peptide analogues of disease-associated epitopes: more than blocking alone. J Exp Med (1992) 1.12
The identification of CD4+ T cell epitopes with dedicated synthetic peptide libraries. Proc Natl Acad Sci U S A (1997) 1.12
T cell positive selection by a high density, low affinity ligand. Proc Natl Acad Sci U S A (1998) 1.12
Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model. Proc Natl Acad Sci U S A (1994) 1.12
Fine specificity and cross-clade reactivity of HIV type 1 Gag-specific CD4+ T cells. AIDS Res Hum Retroviruses (2004) 1.10
Dynamics of signal transduction after aggregation of cell-surface receptors: studies on the type I receptor for IgE. Proc Natl Acad Sci U S A (1994) 1.09
Modulation of T cell development by an endogenous altered peptide ligand. J Exp Med (1995) 1.08
Presentation of a T cell receptor antagonist peptide by immunoglobulins ablates activation of T cells by a synthetic peptide or proteins requiring endocytic processing. J Exp Med (1997) 1.07
Selective activation of Fas/Fas ligand-mediated cytotoxicity by a self peptide. J Exp Med (1996) 1.07
Involvement of both major histocompatibility complex class II alpha and beta chains in CD4 function indicates a role for ordered oligomerization in T cell activation. J Exp Med (1995) 1.06
In vivo antagonism of a T cell response by an endogenously expressed ligand. Proc Natl Acad Sci U S A (1998) 1.04
CD4(+) T cells from lupus-prone mice are hyperresponsive to T cell receptor engagement with low and high affinity peptide antigens: a model to explain spontaneous T cell activation in lupus. J Exp Med (2001) 1.04
Endogenous altered peptide ligands can affect peripheral T cell responses. J Exp Med (1996) 1.01
Similar antigenic surfaces, rather than sequence homology, dictate T-cell epitope molecular mimicry. Proc Natl Acad Sci U S A (1995) 1.01
T cell receptor antagonism interferes with MHC clustering and integrin patterning during immunological synapse formation. J Cell Biol (2004) 1.01
Anergy in peripheral memory CD4(+) T cells induced by low avidity engagement of T cell receptor. J Exp Med (2001) 1.00
Dissociation of intracellular signaling pathways in response to partial agonist ligands of the T cell receptor. J Exp Med (1998) 1.00
Specific tolerance to an acetylcholine receptor epitope induced in vitro in myasthenia gravis CD4+ lymphocytes by soluble major histocompatibility complex class II-peptide complexes. J Clin Invest (1994) 1.00
Design of high-affinity major histocompatibility complex-specific antagonist peptides that inhibit cytotoxic T-lymphocyte activity: implications for control of viral disease. J Virol (1992) 0.99
A peptide composed of tandem analogs of two myasthenogenic T cell epitopes interferes with specific autoimmune responses. Proc Natl Acad Sci U S A (1997) 0.99
Genetic analysis of host-parasite coevolution in human malaria. Philos Trans R Soc Lond B Biol Sci (1997) 0.97
Virus and cytotoxic T lymphocytes: crucial role of viral peptide secondary structure in major histocompatibility complex class I interactions. J Virol (1993) 0.96
Copresentation of natural HIV-1 agonist and antagonist ligands fails to induce the T cell receptor signaling cascade. Proc Natl Acad Sci U S A (1998) 0.96
Persistence of peptide-induced CD4+ T cell anergy in vitro. J Exp Med (1998) 0.96
Major histocompatibility complex class II DR-restricted memory CD4(+) T lymphocytes recognize conserved immunodominant epitopes of Anaplasma marginale major surface protein 1a. Infect Immun (2002) 0.94
Inhibition of T-cell reactivity to myasthenogenic epitopes of the human acetylcholine receptor by synthetic analogs. Proc Natl Acad Sci U S A (1993) 0.94
Differential thymic selection outcomes stimulated by focal structural alteration in peptide/major histocompatibility complex ligands. Proc Natl Acad Sci U S A (1998) 0.93
Inhibition or activation of human T cell receptor transfectants is controlled by defined, soluble antigen arrays. J Exp Med (1992) 0.92
Differential activation of proliferation and cytotoxicity in human T-cell lymphotropic virus type I Tax-specific CD8 T cells by an altered peptide ligand. Proc Natl Acad Sci U S A (1995) 0.91
The contributions of T-cell anergy to peripheral T-cell tolerance. Immunology (2001) 0.91
Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities. Immunology (2001) 0.90
Unresponsiveness to a self-peptide of mouse lysozyme owing to hindrance of T cell receptor-major histocompatibility complex/peptide interaction caused by flanking epitopic residues. J Exp Med (1996) 0.90
T cell recognition of weak ligands: roles of signaling, receptor number, and affinity. Immunol Res (2011) 0.90
The role of CD4-Lck in T-cell receptor antagonism: evidence for negative signaling. Proc Natl Acad Sci U S A (1996) 0.89
Induction of dominant transplantation tolerance by an altered peptide ligand of the male antigen Dby. J Clin Invest (2004) 0.89
Interactions with multiple peptide ligands determine the fate of developing thymocytes. Proc Natl Acad Sci U S A (1998) 0.89
Manipulating antigenic ligand strength to selectively target myelin-reactive CD4+ T cells in EAE. J Neuroimmune Pharmacol (2009) 0.89
F(c)gammaRI-targeted fusion proteins result in efficient presentation by human monocytes of antigenic and antagonist T cell epitopes. J Clin Invest (1996) 0.88
CD3 ligation on immature thymocytes generates antagonist-like signals appropriate for CD8 lineage commitment, independently of T cell receptor specificity. J Exp Med (1998) 0.88
Cyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in celiac disease. Bioorg Med Chem (2007) 0.87
Suboptimal engagement of the T-cell receptor by a variety of peptide-MHC ligands triggers T-cell anergy. Immunology (2009) 0.87
Systemic immunomodulation of autoimmune disease using MHC-derived recombinant TCR ligands. Curr Drug Targets Inflamm Allergy (2005) 0.87
Modulation of the immune response with T-cell epitopes: the ultimate goal for specific immunotherapy of autoimmune disease. Immunology (1994) 0.86
Divergent paths for the selection of immunodominant epitopes from distinct antigenic sources. Nat Commun (2014) 0.86
Functional reprogramming of the primary immune response by T cell receptor antagonism. J Exp Med (2004) 0.86
T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunotherapy (2010) 0.86
Heteroclitic proliferative responses and changes in cytokine profile induced by altered peptides: implications for autoimmunity. Proc Natl Acad Sci U S A (1998) 0.85
Altered peptide ligands regulate muscarinic acetylcholine receptor reactive T cells of patients with Sjögren's syndrome. Ann Rheum Dis (2006) 0.85
Fully competent dendritic cells as inducers of T cell anergy in autoimmunity. Proc Natl Acad Sci U S A (2000) 0.84
The role of peptides in thymic positive selection of class II major histocompatibility complex-restricted T cells. Proc Natl Acad Sci U S A (1998) 0.84
Antagonism of HIV-specific CD4+ T cells by C-terminal truncation of a minimum epitope. Mol Immunol (2005) 0.84
Specific prolongation of allograft survival by a T-cell-receptor-derived peptide. Proc Natl Acad Sci U S A (1993) 0.84
Positive selection of CD4(+) T cells is induced in vivo by agonist and inhibited by antagonist peptides. J Exp Med (2001) 0.83
Differential activation of mouse hepatitis virus-specific CD4+ cytotoxic T cells is defined by peptide length. Immunology (1995) 0.83
Natural epitope variants of the hepatitis C virus impair cytotoxic T lymphocyte activity. World J Gastroenterol (2010) 0.82
Understanding the mechanisms of sustained signaling and T cell activation. J Exp Med (1997) 0.81
Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications. Neurotherapeutics (2016) 0.81
Positive selection in the thymus: an enigma wrapped in a mystery. J Immunol (2012) 0.81
Rational design of nonnatural peptides as high-affinity ligands for the HLA-B*2705 human leukocyte antigen. Proc Natl Acad Sci U S A (1995) 0.80
Flexibility in T-cell receptor ligand repertoires depends on MHC and T-cell receptor clonotype. Immunology (1997) 0.80
The effect of a single amino acid substitution within the V3 loop of HIV-1 gp120 on HLA-DR1-restricted CD4 T-cell recognition. Immunology (1995) 0.79
Altered peptide ligands inhibit arthritis induced by glucose-6-phosphate isomerase peptide. Arthritis Res Ther (2009) 0.79
Selective immunosuppression by administration of major histocompatibility complex class II-binding peptides. II. Preventive inhibition of primary and secondary in vivo antibody responses. J Exp Med (1993) 0.79
Clonal analysis of the T-cell response to in vivo expressed Mycobacterium tuberculosis protein Rv2034, using a CD154 expression based T-cell cloning method. PLoS One (2014) 0.78
Molecular and functional dissection of the H-2Db-restricted subdominant cytotoxic T-cell response to lymphocytic choriomeningitis virus. J Virol (2001) 0.78
Substitutions in a major histocompatibility complex class II-restricted human immunodeficiency virus type 1 gp120 epitope can affect CD4+ T-helper-cell function. J Virol (1998) 0.78
Antagonistic variant virus prevents wild-type virus-induced lethal immunopathology. J Exp Med (2002) 0.78
Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature (2000) 9.80
Immunoglobulins on the surface of lymphocytes. I. Distribution and quantitation. J Exp Med (1971) 8.22
Immunoglobulins on the surface of lymphocytes. II. The bone marrow as the main source of lymphocytes with detectable surface-bound immunoglobulin. J Exp Med (1971) 5.43
The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science (1987) 5.32
Combined studies of complement receptor and surface immunoglobulin-bearing cells and sheep erythrocyte rosette-forming cells in normal and leukemic human lymphocytes. J Clin Invest (1973) 5.31
Immunoglobulins on the surface of lymphocytes. IV. Distribution in hypogammaglobulinemia, cellular immune deficiency, and chronic lymphatic leukemia. J Clin Invest (1971) 4.98
Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef. Nat Med (1999) 4.93
Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med (2001) 4.85
Isolation and characterization of antigen-Ia complexes involved in T cell recognition. Cell (1986) 4.71
Two different complement receptors on human lymphocytes. One specific for C3b and one specific for C3b inactivator-cleaved C3b. J Exp Med (1973) 4.46
ELAM-1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-Lex. Science (1990) 4.45
Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature (1994) 4.42
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol (1994) 4.37
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol (1995) 4.31
Lyme carditis: cardiac abnormalities of Lyme disease. Ann Intern Med (1980) 4.12
The minimal number of class II MHC-antigen complexes needed for T cell activation. Science (1990) 4.09
Randomised controlled trial of psychological debriefing for victims of acute burn trauma. Br J Psychiatry (1997) 3.98
Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol (1998) 3.95
Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell (1993) 3.80
Antigen recognition by H-2-restricted T cells. II. A tryptic ovalbumin peptide that substitutes for processed antigen. J Immunol (1984) 3.72
Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. J Immunol (1998) 3.65
Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells. Nature (1987) 3.63
The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity (2001) 3.52
Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol (1996) 3.45
Differential effects of cytolytic T cell subsets on intracellular infection. Science (1997) 3.39
Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science (1992) 3.39
Studies on the capacity of B cells to serve as antigen-presenting cells. J Immunol (1981) 3.38
Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J Exp Med (1998) 3.35
The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med (1995) 3.34
Analysis of T cell function in autoimmune murine strains. Defects in production and responsiveness to interleukin 2. J Exp Med (1981) 3.27
T cell antigen receptor-mediated activation of phospholipase C requires tyrosine phosphorylation. Science (1990) 3.23
Receptors for aggregated IgG on mouse lymphocytes: their presence on thymocytes, thymus-derived, and bone marrow-derived lymphocytes. J Exp Med (1974) 3.21
Structure and function of immunoglobulin A. Prog Allergy (1972) 3.14
Antigen presentation by normal B cells, B cell tumors, and macrophages: functional and biochemical comparison. J Immunol (1982) 3.08
Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest (1997) 2.99
Receptors for IgG: subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line. J Exp Med (1977) 2.98
A subclass of human gamma-A-globulins (gamma-A2) which lacks the disulfied bonds linking heavy and light chains. J Exp Med (1968) 2.98
The reaction of monomeric and aggregated immunoglobulins with C1. Immunochemistry (1971) 2.96
Gata5 is required for the development of the heart and endoderm in zebrafish. Genes Dev (1999) 2.95
Fusion of host cell secondary lysosomes with the parasitophorous vacuoles of Leishmania mexicana-infected macrophages. J Protozool (1975) 2.93
Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity (1994) 2.90
Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med (1995) 2.80
Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. Proc Natl Acad Sci U S A (1989) 2.73
Rapid activation of the T-cell tyrosine protein kinase pp56lck by the CD45 phosphotyrosine phosphatase. Proc Natl Acad Sci U S A (1989) 2.70
The small subunit of HL-A antigens is beta 2-microglobulin. J Exp Med (1973) 2.68
Presentation of viral antigen controlled by a gene in the major histocompatibility complex. Nature (1990) 2.65
Promoting clinical involvement in hospital quality improvement efforts: the effects of top management, board, and physician leadership. Health Serv Res (1997) 2.65
Reducing the risk of cardiovascular disease: effects of a community-based campaign on knowledge and behavior. J Community Health (1977) 2.64
Macrophage-activating factor produced by a T cell hybridoma: physiochemical and biosynthetic resemblance to gamma-interferon. J Immunol (1983) 2.61
Immunological self, nonself discrimination. Science (1987) 2.59
Relationship between inositol polyphosphate production and the increase of cytosolic free Ca2+ induced by vasopressin in isolated hepatocytes. J Biol Chem (1984) 2.57
Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J Mol Biol (1997) 2.57
Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J Immunol (1999) 2.53
On the interaction of promiscuous antigenic peptides with different DR alleles. Identification of common structural motifs. J Immunol (1991) 2.49
Alcohol and injury. A case-crossover study. Arch Fam Med (1995) 2.49
Interaction between a "processed" ovalbumin peptide and Ia molecules. Proc Natl Acad Sci U S A (1986) 2.42
Protein A reactivity with mouse immunoglobulins. Structural relationship between some mouse and human immunoglobulins. J Immunol (1970) 2.38
Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med (1994) 2.37
Thymus-derived (T) cell immunoglobulins. Presence of a receptor site for IgG and absence of large amounts of "buried" Ig determinants on T cells. J Exp Med (1972) 2.35
Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes. J Immunol (1988) 2.35
Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol (1995) 2.34
Immunoglobulins on the surface of lymphocytes. 3. Bursal origin of surface immunoglobulins on chicken lymphocytes. J Immunol (1971) 2.33
Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc Natl Acad Sci U S A (1989) 2.32
Identification of Db- and Kb-restricted subdominant cytotoxic T-cell responses in lymphocytic choriomeningitis virus-infected mice. Virology (1998) 2.31
Oesophageal narrowing is common and frequently under-appreciated at endoscopy in patients with oesophageal eosinophilia. Aliment Pharmacol Ther (2014) 2.30
Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol (2000) 2.29
A new mouse immunoglobulin: IgG3. J Exp Med (1971) 2.27
A comparison of vascularized and nonvascularized bone grafts for reconstruction of mandibular continuity defects. J Oral Maxillofac Surg (1997) 2.27
Requirements for the processing of antigens by antigen-presenting B cells. I. Functional comparison of B cell tumors and macrophages. J Immunol (1982) 2.25
The interaction between protein-derived immunogenic peptides and Ia. Immunol Rev (1987) 2.24
Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection. J Immunol (1996) 2.24
Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med (1994) 2.18
Antigen-induced translocation of PKC-theta to membrane rafts is required for T cell activation. Nat Immunol (2001) 2.18
Cryoimmunoglobulins. Semin Hematol (1973) 2.18
Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med (1996) 2.17
Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated? J Urol (2000) 2.16
Conserved T cell receptor repertoire in primary and memory CD8 T cell responses to an acute viral infection. J Exp Med (1998) 2.13
NF-kappa B activation induced by T cell receptor/CD28 costimulation is mediated by protein kinase C-theta. Proc Natl Acad Sci U S A (2000) 2.13
Definition of specific peptide motifs for four major HLA-A alleles. J Immunol (1994) 2.11
Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways. Nature (1990) 2.11
Tyrosine kinase-stimulated guanine nucleotide exchange activity of Vav in T cell activation. Science (1993) 2.10
Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat Med (2001) 2.10
CD8+ T cells are the major lymphocyte subpopulation involved in the protective immune response to Toxoplasma gondii in mice. Clin Exp Immunol (1991) 2.10
Class I-induced resistance to natural killing: identification of nonpermissive residues in HLA-A2. Proc Natl Acad Sci U S A (1991) 2.07
Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch Dis Child (2001) 2.07
Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol (1994) 2.07